the disclosure thing is everywhere in these threads, but the part that catches my eye is the assumption baked into it: that you actually know how much of the 30 lbs was the drug. you don’t. not cleanly. diabetes dx usually comes with a behavior change, the drug, and a caloric deficit all starting the same week. three variables moving together. that’s the same failure mode i watch people hit when they stack three peptides and then can’t tell which one did anything. you changed three things at once, so “it’s the mounjaro” is a guess wearing a lab coat. i’m not in the GLP-1 world, i came at this from rotator cuff recovery and a lot of ROM logging, but the methodology transfers cleanly. the question isn’t social, it’s: what’s your baseline and what are you actually tracking against. if you want a real answer instead of a vibe: - your A1C is the closest thing to a clean number you have. it’s a ~3 month average, so it lags, but it’s not a sensation, it’s data. weight is noisier day to day than people admit, water and sodium swing it a couple lbs on their own.
- log shot day. tirz half-life is ~5 days, so appetite isn’t flat across the week, it ramps and fades. if you don’t note the day you pinned you can’t see that pattern at all.
- track food intake separately from the drug if you can. that’s the only way you ever separate “the drug killed my appetite” from “i also started walking and cooking.” i used a tracker for the shoulder stuff for exactly this reason, my PT kept asking how i felt two weeks prior and i had nothing. the correlation view was where i first saw my ROM dips line up with bad sleep nights, which i’d never have caught eyeballing it. same tool would show you weight vs shot-day timing. so when someone asks, “diabetes meds plus i cut back, honestly can’t tell you the split” is the most accurate thing you can say. it’s not dishonest. it’s just admitting the variable was never isolated. what’s your A1C doing? that’s the number i’d actually want.
“closest thing to a clean number” - worth pulling on that a bit. the case for A1C is real: it’s a rolling average, it’s not mood or water retention, it doesn’t lie about yesterday’s sodium. but the 3-month lag doesn’t solve the isolation problem you’re correctly identifying. imo if the dx, the drug, and the behavior change all started week one, your month-3 A1C is still a weighted composite of all three inputs. it’s less noisy, not more isolated.
“less noisy, not more isolated” is exactly right, and i should’ve said it that way in the OP. month-3 A1C is a weighted composite of all three inputs, you can’t back out the drug’s share from it. where i’d split off though: isolation was already gone the week everything started together, and no single number recovers it after the fact. so i don’t think A1C’s job is to isolate. its job is the feedback loop on whether the current dose is doing anything at all, which is a different question than “what was the drug worth.” you lost the clean baseline, but two points still beat one. pull A1C now, pull it again next quarter, and the delta tells you trajectory even if it can’t hand you the split. the only way you’d ever isolate is staggering the variables in time, and a dx forces them all on in week one, so realistically nobody gets that. fwiw the thing that actually showed me a pattern was lining up daily entries in a correlation view, weight against shot-day timing, not any one lab value carrying the whole load.
the lean mass variable is the one this framing keeps skipping over. 30 lbs on a scale is a different outcome depending on how much was fat vs muscle, and tirz has a documented lean mass loss component that showed up in the SURMOUNT-1 subgroups, not trivial, and not evenly distributed across the cohort. A1C and scale weight are both downstream of the intervention, but neither tells you what you actually traded for the loss, and if long-term metabolic health is part of why you’re doing this in the first place, the composition split matters as much as the aggregate number. DEXA is annoying to access and not cheap, but it’s the only read that shows you the composition story rather than forcing you to infer it from scale weight alone. someone who lost 30 lbs mostly from lean mass is in a genuinely different metabolic position than someone who lost 30 mostly from fat, and the scale and A1C together still don’t resolve which one you are.
The case for rigorous baseline tracking is solid, and the ROM-logging parallel is genuinely useful framing. But “three variables moving together” assumes the behaviour change and the drug are independent, and for GLP-1 agonists that assumption is shakier than it looks. Reduced appetite, diminished food noise, earlier satiety - those aren’t happening in parallel with tirzepatide, they’re largely mechanistic outputs of it. So calling diet change a separate variable conflates cause and downstream effect in a way that the peptide-stacking analogy doesn’t quite map onto. The stacking critique holds bc you really can’t disentangle BPC from TB-500 when both go in simultaneously. But “started walking and cooking” after tirz initiation is more plausibly the drug driving the behaviour than two separate interventions occurring by coincidence. The attribution question is still messy, agreed. It’s just not the same logical structure as three truly independent variables, and collapsing them overstates the confounding.
eta: one more thing